122 related articles for article (PubMed ID: 20582983)
61. Encouraging Clinical Evolution of a Pediatric Patient With Relapsed Diffuse Midline Glioma Who Underwent WT1-Targeting Immunotherapy: A Case Report and Literature Review.
Hashii Y; Oka Y; Kagawa N; Hashimoto N; Saitou H; Fukuya S; Kanegae M; Ikejima S; Oji Y; Ozono K; Tsuboi A; Sugiyama H
Front Oncol; 2020; 10():1188. PubMed ID: 32793489
[TBL] [Abstract][Full Text] [Related]
62. Immunohistochemical Analysis of WT1 Antigen Expression in Various Solid Cancer Cells.
Naitoh K; Kamigaki T; Matsuda E; Ibe H; Okada S; Oguma E; Kinoshita Y; Takimoto R; Makita K; Ogasawara S; Goto S
Anticancer Res; 2016 Jul; 36(7):3715-24. PubMed ID: 27354645
[TBL] [Abstract][Full Text] [Related]
63. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.
Dao T; Yan S; Veomett N; Pankov D; Zhou L; Korontsvit T; Scott A; Whitten J; Maslak P; Casey E; Tan T; Liu H; Zakhaleva V; Curcio M; Doubrovina E; O'Reilly RJ; Liu C; Scheinberg DA
Sci Transl Med; 2013 Mar; 5(176):176ra33. PubMed ID: 23486779
[TBL] [Abstract][Full Text] [Related]
64. Wilms' tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory acute leukemia.
Ogasawara M; Miyashita M; Yamagishi Y; Ota S
Ther Apher Dial; 2022 Jun; 26(3):537-547. PubMed ID: 35249263
[TBL] [Abstract][Full Text] [Related]
65. WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1.
Oji Y; Kagawa N; Arita H; Naka N; Hamada KI; Outani H; Shintani Y; Takeda Y; Morii E; Shimazu K; Suzuki M; Nishida S; Nakata J; Tsuboi A; Iwai M; Hayashi S; Imanishi R; Ikejima S; Kanegae M; Iwamoto M; Ikeda M; Yagi K; Shimokado H; Nakajima H; Hasegawa K; Morimoto S; Fujiki F; Nagahara A; Tanemura A; Ueda Y; Mizushima T; Ohmi M; Ishida T; Fujimoto M; Nonomura N; Kimura T; Inohara H; Okada S; Kishima H; Hosen N; Kumanogoh A; Oka Y; Sugiyama H
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672344
[TBL] [Abstract][Full Text] [Related]
66. Post-transplant immunotherapy with WT1-specific CTLs for high-risk acute myelogenous leukemia: a prospective clinical phase I/II trial.
Kim HJ; Sohn HJ; Hong JA; Lee HJ; Sohn DH; Shin CA; Cho HI; Min WS; Kim TG
Bone Marrow Transplant; 2019 Jun; 54(6):903-906. PubMed ID: 30410082
[No Abstract] [Full Text] [Related]
67. [Immunotherapy of neoplasms with special consideration of leukemia].
Kotlarek-Haus S
Pol Arch Med Wewn; 1979 Aug; 62(2):127-35. PubMed ID: 503893
[No Abstract] [Full Text] [Related]
68. Letter from the editor.
Hum Vaccin Immunother; 2015; 11(4):807. PubMed ID: 25933179
[No Abstract] [Full Text] [Related]
69. WT1 peptide-based immunotherapy for refractory thymic epithelial malignancies.
Suzuki M; Hishida T; Asakura K; Asamura H
Mediastinum; 2019; 3():12. PubMed ID: 35118240
[No Abstract] [Full Text] [Related]
70. Administration of a glypican-3 peptide increases the infiltration and cytotoxicity of CD8
Zhao J; Qin L; He G; Xie T; Hu G; Wang F; Zhong H; Zhu J; Xu Y
Cancer Med; 2023 Dec; 12(23):21293-21307. PubMed ID: 37986544
[TBL] [Abstract][Full Text] [Related]
71. Wilms' Tumor 1 (WT1): The Vaccine for Cancer.
Hein KZ; Yao S; Fu S
J Immunother Precis Oncol; 2020 Nov; 3(4):165-171. PubMed ID: 35665371
[TBL] [Abstract][Full Text] [Related]
72. Immunotherapy Associated Neurotoxicity in Pediatric Oncology.
Shalabi H; Nellan A; Shah NN; Gust J
Front Oncol; 2022; 12():836452. PubMed ID: 35265526
[TBL] [Abstract][Full Text] [Related]
73. Therapeutic cancer vaccines for pediatric malignancies: advances, challenges, and emerging technologies.
Olsen HE; Lynn GM; Valdes PA; Cerecedo Lopez CD; Ishizuka AS; Arnaout O; Bi WL; Peruzzi PP; Chiocca EA; Friedman GK; Bernstock JD
Neurooncol Adv; 2021; 3(1):vdab027. PubMed ID: 33860227
[TBL] [Abstract][Full Text] [Related]
74. Human CLEC9A antibodies deliver Wilms' tumor 1 (WT1) antigen to CD141
Pearson FE; Tullett KM; Leal-Rojas IM; Haigh OL; Masterman KA; Walpole C; Bridgeman JS; McLaren JE; Ladell K; Miners K; Llewellyn-Lacey S; Price DA; Tunger A; Schmitz M; Miles JJ; Lahoud MH; Radford KJ
Clin Transl Immunology; 2020; 9(6):e1141. PubMed ID: 32547743
[TBL] [Abstract][Full Text] [Related]
75. Efficacy of the NCCV Cocktail-1 vaccine for refractory pediatric solid tumors: A phase I clinical trial.
Akazawa Y; Hosono A; Yoshikawa T; Kaneda H; Nitani C; Hara J; Kinoshita Y; Kohashi K; Manabe A; Fukutani M; Wakabayashi M; Sato A; Shoda K; Shimomura M; Mizuno S; Nakamoto Y; Nakatsura T
Cancer Sci; 2019 Dec; 110(12):3650-3662. PubMed ID: 31571332
[TBL] [Abstract][Full Text] [Related]
76. Dendritic Cell-Based and Other Vaccination Strategies for Pediatric Cancer.
de Bruijn S; Anguille S; Verlooy J; Smits EL; van Tendeloo VF; de Laere M; Norga K; Berneman ZN; Lion E
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31546858
[TBL] [Abstract][Full Text] [Related]
77. WT1 as an immunotherapy target for thymic epithelial tumors: a novel method to activate anti-tumor immunity.
Takahashi N; Zhao C; Rajan A
Mediastinum; 2019 Apr; 3():. PubMed ID: 31304461
[No Abstract] [Full Text] [Related]
78. Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors.
Tsuchiya N; Hosono A; Yoshikawa T; Shoda K; Nosaka K; Shimomura M; Hara J; Nitani C; Manabe A; Yoshihara H; Hosoya Y; Kaneda H; Kinoshita Y; Kohashi K; Yoshimura K; Fujinami N; Saito K; Mizuno S; Nakatsura T
Oncoimmunology; 2017; 7(1):e1377872. PubMed ID: 29296538
[TBL] [Abstract][Full Text] [Related]
79. Development of oral cancer vaccine using recombinant Bifidobacterium displaying Wilms' tumor 1 protein.
Kitagawa K; Oda T; Saito H; Araki A; Gonoi R; Shigemura K; Hashii Y; Katayama T; Fujisawa M; Shirakawa T
Cancer Immunol Immunother; 2017 Jun; 66(6):787-798. PubMed ID: 28299466
[TBL] [Abstract][Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
